SCHEMBL20005716

SCHEMBL20005716

CC(C)(C)OC(=O)NCC1(c2cc(F)cc(F)c2)CC1CO

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 2/20 0.35
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
DRD2 P14416 3/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
DPP8 Q6V1X1 2/20 0.32
DPP9 Q86TI2 2/20 0.32
GRM2 Q14416 1/20 0.32
CPB2 Q96IY4 2/20 0.32
SERPINE1 P05121 1/20 0.32
KDM4A O75164 1/20 0.32
EPHX1 P07099 1/20 0.32
APLNR P35414 1/20 0.32
HCRTR1 O43613 1/20 0.31
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20005977 1.00 HCRTR2 (0.35) HCRTR2NFKB1NFKB2RELATDP1
SCHEMBL20005832 0.87 MAOA (0.36) HCRTR2NFKB1NFKB2RELADRD2
SCHEMBL20005952 0.86 CTSS (0.37) HCRTR2CPB2
SCHEMBL13720547 0.83 IDO1 (0.41) DRD2ALDH1A1KMT2ACPB2KDM4A
SCHEMBL29891320 0.82 DPP8 (0.38) HCRTR2DRD2DPP8DPP9GRM2
SCHEMBL21135750 0.82 DPP8 (0.38) HCRTR2DRD2DPP8DPP9GRM2
SCHEMBL19995718 0.81 HCRTR1 (0.32) HCRTR2HCRTR1KCNH2
SCHEMBL21527848 0.81 HCRTR1 (0.32) HCRTR2HCRTR1KCNH2
SCHEMBL13698145 0.81 SLC6A3 (0.48) DRD2
SCHEMBL22917996 0.81 SLC6A3 (0.48) DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2022-01-20 US disclosed
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors BIAL—PORTELA & CA, S.A. (PT) 2021-04-13 US disclosed
WO-2018056854-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS DBH, SLC6A3, SLC6A2 HCRTR2 341/4885NFKB1 2638/4885NFKB2 3281/4885
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors DBH, SLC6A3, SLC6A2 HCRTR2 361/4885NFKB1 2499/4885NFKB2 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.